- Home
- RIGL vs BWMX Comparison
RIGL vs BWMX Comparison
Compare RIGL & BWMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BWMX
- Stock Information
- Founded
- RIGL 1996
- BWMX 1995
- Country
- RIGL United States
- BWMX Mexico
- Employees
- RIGL N/A
- BWMX N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BWMX Catalog/Specialty Distribution
- Sector
- RIGL Health Care
- BWMX Consumer Discretionary
- Exchange
- RIGL Nasdaq
- BWMX Nasdaq
- Market Cap
- RIGL 335.5M
- BWMX 495.6M
- IPO Year
- RIGL 2000
- BWMX N/A
- Fundamental
- Price
- RIGL $38.85
- BWMX $13.29
- Analyst Decision
- RIGL Buy
- BWMX Strong Buy
- Analyst Count
- RIGL 5
- BWMX 1
- Target Price
- RIGL $38.20
- BWMX $22.50
- AVG Volume (30 Days)
- RIGL 995.6K
- BWMX 55.5K
- Earning Date
- RIGL 08-05-2025
- BWMX 10-23-2025
- Dividend Yield
- RIGL N/A
- BWMX 10.75%
- EPS Growth
- RIGL N/A
- BWMX N/A
- EPS
- RIGL 5.43
- BWMX 0.84
- Revenue
- RIGL $267,921,000.00
- BWMX $751,432,052.00
- Revenue This Year
- RIGL $59.93
- BWMX $6.54
- Revenue Next Year
- RIGL N/A
- BWMX $6.09
- P/E Ratio
- RIGL $7.15
- BWMX $15.88
- Revenue Growth
- RIGL 105.62
- BWMX 4.83
- 52 Week Low
- RIGL $12.66
- BWMX $7.00
- 52 Week High
- RIGL $43.72
- BWMX $14.46
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- BWMX 62.09
- Support Level
- RIGL $39.00
- BWMX $13.06
- Resistance Level
- RIGL $42.08
- BWMX $13.50
- Average True Range (ATR)
- RIGL 2.32
- BWMX 0.45
- MACD
- RIGL -0.37
- BWMX -0.13
- Stochastic Oscillator
- RIGL 53.26
- BWMX 66.64
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.